OncoMatch/Clinical Trials/NCT06617000
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Is NCT06617000 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SCG101 for hcc.
Treatment: SCG101 — This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Demographics
Prior therapy
Must have received: standard systemic therapies
Subjects with HCC who have received standard systemic therapies
Cannot have received: cell therapy (killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy)
Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy
Lab requirements
Liver function
child-pugh score ≤ 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06617000 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages